291 related articles for article (PubMed ID: 8821075)
1. Twenty-five years of amantadine therapy in Parkinson's disease.
Danielczyk W
J Neural Transm Suppl; 1995; 46():399-405. PubMed ID: 8821075
[TBL] [Abstract][Full Text] [Related]
2. Amantadine in Parkinson's disease: pro and contra.
Greulich W; Fenger E
J Neural Transm Suppl; 1995; 46():415-21. PubMed ID: 8821077
[TBL] [Abstract][Full Text] [Related]
3. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
Fischer PA
J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
[TBL] [Abstract][Full Text] [Related]
4. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Hill MP; Ravenscroft P; Bezard E; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
J Pharmacol Exp Ther; 2004 Jul; 310(1):386-94. PubMed ID: 15004218
[TBL] [Abstract][Full Text] [Related]
5. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
6. [Initiation of treatment in Parkinson disease].
Ghika J
Praxis (Bern 1994); 1995 Sep; 84(38):1018-20. PubMed ID: 7481298
[TBL] [Abstract][Full Text] [Related]
7. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
8. [Comparison between the effects of L-dopa, prodipine and amantadine on the serum and CSF amino acid levels in Parkinson's disease (author's transl)].
Gründig E; Gerstenbrand F
Wien Klin Wochenschr; 1980 Dec; 92(24):868-71. PubMed ID: 7222702
[TBL] [Abstract][Full Text] [Related]
9. [Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease].
Dzudza M; Dzudza D
Med Arh; 1974; 28(4):407-15. PubMed ID: 4613968
[No Abstract] [Full Text] [Related]
10. Parkinson's disease: drug therapy.
Oertel WH; Quinn NP
Baillieres Clin Neurol; 1997 Apr; 6(1):89-108. PubMed ID: 9426870
[TBL] [Abstract][Full Text] [Related]
11. The L-dopa sparing effect of G 31,406 in the treatment of parkinson's disease.
Couto B; Oliveira C; Mattos JP; Freitas MR
Neurol Neurocir Psiquiatr; 1976; 17(4):285-92. PubMed ID: 798128
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
13. [Initial treatment of Parkinson's disease].
Kulisevsky J; López-Villegas D
Rev Neurol; 1997 Aug; 25 Suppl 2():S163-9. PubMed ID: 9280684
[TBL] [Abstract][Full Text] [Related]
14. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
Cersósimo MG; Scorticati MC; Micheli FE
Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
[TBL] [Abstract][Full Text] [Related]
15. Peculiarities of L: -DOPA treatment of Parkinson's disease.
Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
[TBL] [Abstract][Full Text] [Related]
16. [Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient].
Ceballos-Baumann AO
MMW Fortschr Med; 2002 May; Suppl 2():37-43. PubMed ID: 12070848
[TBL] [Abstract][Full Text] [Related]
17. [Recent aspects of Parkinson therapy].
Jörg J; Janssen A
Z Gerontol; 1987; 20(1):38-43. PubMed ID: 3107231
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease in the elderly: current management strategies.
Aminoff MJ
Geriatrics; 1987 Jul; 42(7):31-7. PubMed ID: 3110015
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic effects of dopamine replacement therapy and its psychiatric side effects are mediated by pineal function.
Willis GL
Behav Brain Res; 2005 May; 160(1):148-60. PubMed ID: 15836910
[TBL] [Abstract][Full Text] [Related]
20. Dropped head associated with amantadine in Parkinson disease.
Kataoka H; Ueno S
Clin Neuropharmacol; 2011; 34(1):48-9. PubMed ID: 21242745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
